The UAE has become the second country in the world to approve the new lung cancer drug 'Lumakras'.
The Ministry of Health and Prevention (MoHAP) has cleared the registration and use of the drug, which recently received the approval of the US Food and Drug Administration (FDA).
It will help speed up the treatment plan of patients in the UAE and improve their quality of life.
Lumakras, manufactured by Amgen, is prescribed to adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received at least one previous cancer therapy.
It is supplied as film-coated tablets for oral use containing 120 mg of sotorasib.
UAE President calls for stronger global cooperation at G7 Summit
UAE foils drug distribution plot, dismantles criminal network
Sharjah Ruler unveils AED 750 million projects to link direct roads to Dubai
UAE President meets US President on sidelines of G7 Summit
UAE President, Greek PM discuss strategic cooperation
Emirati Media Forum to address misinformation, AI and industry transformation
UAE introduces new Emiratisation rules for healthcare sector
